SAI LIFE SCIENCES LIMITED
Latest filings
Next results: Thu, 5 Nov · Financial Results- Earnings call scheduled for Q2 FY27 results on Nov 6, 2026 · Board & Shareholder Meetings
- 54,500 equity shares allotted under ESOP 2008 · Capital Market Events
- Routine compliance certificate on share dematerialization for Q2 FY2027 · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates two service lines for pharmaceutical clients: Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO). The CDMO business generated ₹1,417 crore in FY26, up 33% year-on-year, while the CRO business generated ₹775 crore, up 24% year-on-year. Together they delivered ₹2,192.49 crore in revenue for FY26, a 29% rise over the prior year. EBITDA reached ₹661 crore at a 30.66% margin, with net profit of ₹348.91 crore. A front-loaded capex of ₹1,100-1,300 crore is planned for FY27 — versus ₹633 crore in FY26 — with 62% allocated to CDMO and 38% to CRO/capabilities, aimed at nearly doubling manufacturing capacity by FY27. The largest cost lines are employees at 31.2% of revenue and materials at 26.4%, followed by other operating expenses (14%) and depreciation (7.6%). Middle East geopolitical tensions have raised input and logistics costs, prompting customer discussions on cost revisions.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SAI LIFE SCIENCES LIMITED's filed financials and exchange disclosures
What does SAI LIFE SCIENCES LIMITED do?
SAI LIFE SCIENCES LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SAILIFE.
Is SAI LIFE SCIENCES LIMITED profitable?
Yes. Over the trailing twelve months SAI LIFE SCIENCES LIMITED reported a net profit of ₹362 Cr on revenue of ₹2,250 Cr.
Does SAI LIFE SCIENCES LIMITED pay a dividend?
Not in the latest reported year — SAI LIFE SCIENCES LIMITED's dividend payout for FY26 was nil.
Is SAI LIFE SCIENCES LIMITED debt-free?
No. It reported borrowings of ₹95 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹13 Cr after cash. Debt stands at 0.04× equity. That is lower than 66% of its 166 Pharmaceuticals peers.
Is SAI LIFE SCIENCES LIMITED expensive compared with its peers?
On trailing P/E, SAI LIFE SCIENCES LIMITED ranks 138 of 158 in Pharmaceuticals — cheaper than 13% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the SAI LIFE SCIENCES LIMITED share price move in a day?
On a typical session SAI LIFE SCIENCES LIMITED moves 1.18% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
When are SAI LIFE SCIENCES LIMITED's next results?
Financial Results on Thu, 5 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track SAI LIFE SCIENCES LIMITED's announcements?
Every NSE and BSE filing by SAI LIFE SCIENCES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.